Vir Biotechnology
This sponsor has funded 2 studies across 7 countries.
| EU PAS ID | Status | RMP requirement | Title | Protocol uploaded | Results uploaded |
|---|---|---|---|---|---|
| 47006 | Finalised | EU RMP category 3 | An open-label, non-comparator, multicenter study to describe the pharmacokinetics (PK), pharmacodynamics (PD; viral load) and safety following a... | No | No |
| 103974 | Finalised | Non-EU RMP-only | XEVUDY General Drug Use Investigation (SARS-CoV-2 Infection) - COVID-19 (217893) | Yes | No |
PAS by Risk Management Plan (RMP) requirement
Vir Biotechnology
The RMP for a medical product outlines strategies to identify, assess, and mitigate risks, including PAS for further evaluation.
Category 1 studies are imposed as condition of marketing authorisation.
Category 2 studies are imposed as specific obligation of marketing authorisation.
Category 3 studies are required under other circumstances.
PAS by study status
Vir Biotechnology
The study status is defined according to the timeline dates specified.
Planned studies have not collected any data yet.
Ongoing studies collect data and should publish protocols as soon as possible.
Finalised studies should publish results in the first two weeks after finalisation.
Countries
Vir Biotechnology
7 Study countries specified are the following:
- Brazil
- Colombia
- Greece
- Japan
- Philippines
- South Africa
- United States